Introduction
============

Soft tissue sarcomas (STSs) are a heterogeneous group of tumors classified by the somatic tissue they resemble, with over 50 subtypes that can be distinguished ([@B11]). The incidence of STS is relatively low -- with estimated 4--5 cases per 100,000 per year ([@B45]) -- but the 5-year survival is only around 50% ([@B13]). Although treatment of STS usually consists of a wide resection of the tumor, followed by radio- or chemotherapy in selected cases ([@B5]), relapses and metastases are still an urgent clinical issue ([@B44]). Due to the heterogeneity in genetics and phenotypes of the different STS entities, many of the proposed laboratory biomarkers and clinical factors still are insufficient for a satisfying prognostic evaluation of the individual patient's outcome.

Human endogenous retroviruses (HERVs) are a class of retroviral sequences acquired during evolution by integration of viral genes in the host genome. They became non-infectious by mutation or loss of relevant genes for replication or virus release ([@B47]). They comprise an estimated 8% of the human genome ([@B32]), and at least 22 independent families based on their homology to known mammalian retroviruses exist ([@B18]).

Among the different families, retroviral sequences of the HERV-K family (HML-2) were the latest acquired, therefore they are the most complete and biologically active family ([@B1]; [@B20], [@B21]). HERV-K expression was detected in several tumor entities, among them chronic myeloid leukemia ([@B3]), renal cell carcinoma ([@B14]; [@B30]), breast carcinoma ([@B49]), prostate carcinoma ([@B48]), pancreatic cancer ([@B34]), and melanoma ([@B43]). In melanoma, HERV-K expression is suggested to be an early event in tumorigenesis, seemingly enhancing the pathological process of tumor formation ([@B43]; [@B6]). Most recently, it was demonstrated that shRNA-mediated downregulation of HERV-K in pancreatic cancer cell lines suppressed growth rates and metastases as well as the expression of several proliferation-related genes ([@B34]). However, it is worth mentioning that the above described associations between HERV expression and tumor tissues are correlative. It has also been demonstrated, that healthy tissues of different origins express HERV sequences, especially during early embryo development and placentation or in the innate immune response (reviewed in [@B37]).

HERV-F is another family of HERVs originally identified by cloning of human genomic DNA sequences and homology analyses ([@B28],[@B29]). HERV-F expression was described in leukemia cell lines ([@B38]) and in a wide range of other tumor cell lines ([@B51]). On the contrary, in adult somatic tissues HERV-F is only expressed in placenta ([@B28]; [@B51]). Recently, constitutive HERV-F expression was reported in a cohort of breast cancer patients, with an increased expression of HERV-F members in comparison to normal breast tissue ([@B15]).

The knowledge on the expression and clinical impact of HERV-K and HERV-F family in STS is scarce. [@B40] reported a robust expression of HERV-K-MEL in human sarcoma specimens, which was higher than in other tumor entities and comparable to the expression in bladder and breast carcinoma, but lower than in melanoma samples. We hypothesized that a detectable HERV mRNA expression could be a common feature in STS and might be related to the patients' clinical outcome. Therefore, the aim of this study was the quantification of HERV-K and HERV-F family mRNA expression in a cohort of 120 STS samples and the correlation to clinicopathological and prognostic data of the patients. Furthermore, as a secondary end point we analyzed the correlation of the mRNA expression of HERV-K and HERV-F with the RNA expression of known apoptosis-related \[B-cell cll/lymphoma 2 (BCL2)\] or hypoxia-related (miR-210, miR-199a, Hypoxia inducible factor 1a) genes as well as known epigenetically regulated genes (miR-203, H2A.Bbd).

Materials and Methods {#s1}
=====================

Patients
--------

One hundred and twenty STS patients agreed to participate in this study. An overview of the patient cohort is given in **Table [1](#T1){ref-type="table"}**. Patients underwent tumor surgical resection between 1998 and 2001 at the Department of Surgery, University of Leipzig (Leipzig, Germany) without prior adjuvant treatment. Thirty-nine patients exhibited metastases (32.5%). Fresh tumor tissue was snap-frozen immediately after excision and stored at -80°C until RNA isolation. The study was approved by the local ethics committee of the Medical Faculty of the Martin Luther University of Halle-Wittenberg and the Medical Faculty of the University of Leipzig. According to the Helsinki Declaration, all patients gave written informed consent. Patient cohort composition as well as tissue cryopreservation was as described previously ([@B24]; [@B50]).

###### 

Clinical and histopathological characteristics in relation to HERV-K and HERV-F mRNA expression.

                                               HERV-K low (\<0.56)   HERV-K high (\>0.56)   Chi^2^ test (*p*-value)   HERV-F low (\<2.02)   HERV-F high (\>2.02)   Chi^2^ test (*p*-value)
  ----------------------- -------------------- --------------------- ---------------------- ------------------------- --------------------- ---------------------- -------------------------
  Age                     \<60 years           28                    35                     n.s.                      31                    32                     n.s.
                          \>60 years           32                    25                                               29                    28                     
  Sex                     Female               25                    30                     n.s.                      25                    30                     n.s.
                          Male                 35                    30                                               35                    30                     
  Patients status         Alive                34                    27                     n.s.                      31                    30                     n.s.
                          Deceased             26                    33                                               29                    30                     
  Tumor stage^a^          I                    9                     4                      n.s.                      7                     6                      n.s.
                          II                   21                    34                                               25                    30                     
                          III                  22                    17                                               21                    18                     
                          IV                   8                     5                                                7                     6                      
  Resection               Radical (R0)         41                    43                     n.s.                      39                    45                     n.s.
                          Not radical (R1)     19                    17                                               21                    15                     
  Tumor localization      Extremities          34                    42                     n.s.                      40                    36                     n.s.
                          Trunk wall           6                     4                                                4                     6                      
                          Head/neck            2                     2                                                3                     1                      
                          Abdomen/peritoneum   17                    9                                                12                    14                     
                          Multiple locations   1                     1                                                1                     1                      
  Histological subtypes   LS                   15                    9                      n.s.                      15                    9                      **0.047**
                          FS                   2                     4                                                1                     5                      
                          RMS                  5                     3                                                5                     3                      
                          LMS                  12                    7                                                6                     13                     
                          NS                   4                     10                                               4                     10                     
                          Syn                  2                     8                                                4                     6                      
                          NOS                  15                    16                                               19                    12                     
                          Other                5                     3                                                6                     2                      
  Tumor size              T1                   9                     10                     n.s.                      7                     12                     n.s.
                          T2                   51                    50                                               53                    48                     
  Number of relapses      0                    43                    31                     (0.077)                   37                    37                     n.s.
                          1                    7                     13                                               10                    10                     
                          \>2                  10                    16                                               13                    13                     
  Metastases              M0                   45                    36                     n.s.                      46                    35                     n.s.
                          M1                   15                    24                                               14                    25                     
                                                                                                                                                                   

One significant association (Chi

2

test) is marked in bold.

a

Union for International Cancer Control Guidelines; LS, liposarcoma; FS, fibrosarcoma; RMS, rhabdomyosarcoma; LMS, leiomyosarcoma; NS, neuronal sarcoma; Syn, synovial sarcoma; NOS, not other specified; T1, \<5 cm in diameter; T2, \>5 cm in diameter.

RNA Isolation
-------------

Tissue specimens were partly processed on a cryotome in 5 μm tissue slices, and RNA was isolated from 20 tissue slices. The slices were incubated in Trizol (Thermo Fisher Scientific, Waltham, MA, United States) for 5 min at room temperature and subsequently mixed with chloroform (AppliChem, Darmstadt, Germany). After centrifugation, aqueous phase was collected and treated with DNase (Qiagen, Hilden, Germany). Total RNA was precipitated with isopropanol (AppliChem, Darmstadt, Germany) for 12 h at 4°C, washed with different ice-cooled ethanol solutions (96 and 70%) and finally dissolved in RNase-free water (Qiagen, Hilden, Germany). RNA concentrations were assessed spectrometrically.

cDNA Synthesis and qPCR
-----------------------

cDNA synthesis was carried out with RevertAid First strand synthesis kit (Thermo Fisher Scientific, Waltham, MA, United States) according to manufacturer's protocol. One μg total RNA was applied for cDNA synthesis per tissue specimen. The complete elimination of genomic DNA was controlled by mock-RT PCR reactions (see Supplementary Figures [S1, S2](#SM1){ref-type="supplementary-material"}). cDNA was quantified with Maxima SyBR Green Kit (Thermo Fisher Scientific, Waltham, MA, United States) in a quantitative real-time-PCR reaction. The applied primer sequences for the PCR reaction were: HERV-K forward: 5′-GGC CAT CAG AGT CTA AAC CAC G-3′; HERV-K reverse: 5′-CTG ACT TTC TGG GGG TGG CCG-3′; HERV-F forward: 5′-CCT CCA GTC ACA ACA ACT C-3′; HERV-F reverse: 5′-TAT TGA AGA AGG CGG CTG G-3′ ([@B42]); H2A.Bbd forward: 5′-TCG TTT TCA GTA GCC AGG T-3′; H2A.Bbd reverse: 5′-CAG AAT TAA TGA AGG CCC AAG-3′; HPRT forward: 5′-TTG CTG ACC TGC TGG ATT AC-3′; HPRT reverse: 5′-CTT GCG ACC TTG ACC ATC TT-3′. Samples were run on a MyIQ cycler (BioRad, Hercules, CA, United States) and HERV-K or HERV-F expression calculated according to the 2^-ΔCT^ method ([@B41]) with HPRT as reference gene. Linearity of the qPCR reaction for both HERV-K and HERV-F was analyzed by dilution series of the gel-extracted amplicon (see Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}). All amplicons were analyzed by qPCR melt analyses on the occurrence of a single, distinct peak (see Supplementary Figures [S4, S5](#SM1){ref-type="supplementary-material"}). Representative PCR products were purified by agarose gel electrophoresis and subsequently sequenced (see **Table [2](#T2){ref-type="table"}**). Analysis of the sequenced PCR products with RepeatMasker ^[1](#fn01){ref-type="fn"}^ demonstrated that the used primers amplified sequences from HERV-K and HERV-Fb (HERVFH21). Expression analyses for BCL2 mRNA, miR-203 and miR-210 ([@B17]), HIF-1α mRNA ([@B25]) and miR-199a ([@B27]) were carried out as previously described.

###### 

Sequence information on HERV-K and HERV-F amplicons.

           Amplicon length (bp)   qPCR melt analysis   Confirmed by sequencing   Amplicon sequence
  -------- ---------------------- -------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HERV-K   167                    Single peak          Yes                       5′-GGCCATCAGAGTCTAAACCACGAGGNACAAGT CCTCTTCCAGCAGGTCAGGT GCCNGTAACATTACAACCTCAAAcGCAGGTTAAAGAAAATAAGACCCAA CCGCC AGTAGCYTATCAATACTGGCCGCCGGCTGAACTTCAGTATCGGCCACCCCC AGAAAGTCAG-3′
  HERV-F   129                    Single peak          Yes                       5′-CCTCCAGTCACAACAACTCACGTGG ACTGTCCTCCCTCAGGNCTTCCAG GATAGCCttcttttctTCGGGCAAGCCCTAGCCCAAGACCTTGCCTCCTTGGATCTTT CCCCCAGCCGCCTTCTTCAATA-3′
                                                                                 

Statistical Analyses
--------------------

Statistical analyses were performed with SPSS 20.0 (IBM Statistics, Ehingen, Germany). HERV expression data were analyzed with bivariate correlation analyses (Spearman rank correlation) and Chi^2^ tests. Survival analyses were performed with Kaplan--Meier analyses and multivariate Cox's Regressions analyses adjusted for resection status, localization of the tumor, tumor entity, and tumor stage (inclusion).

Results
=======

HERV-K and -F Expression in Soft Tissue Sarcoma Samples
-------------------------------------------------------

HERV-K mRNA expression was detected in 120 patients samples with a mean expression of 4.1 (range: 0.06--95.6; 2^-ΔCT^ value). HERV-F mRNA expression was also detected in 120 patients sarcoma specimen with a mean expression of 6.0 (range: 1 × 10^-5^--99.3; 2^-ΔCT^ value, see **Figures [1A,B](#F1){ref-type="fig"}**). Additionally, we measured the HERV-K and HERV-F mRNA expression in normal skeletal muscle tissue. HERV-K mRNA expression was determined at 0.093 (2^-ΔCT^ value) and HERV-F mRNA expression at 0.296 (2^-ΔCT^ value). Skeletal muscle tissue therefore exhibited lower HERV mRNA values than 76.6 and 78.3% of STS samples, respectively. For survival analyses, HERV-K or HERV-F mRNA expression were classified according to the median as cut-off value (HERV-K: 0.56; HERV-F: 2.02). In Chi^2^ tests, low or elevated HERV-K expressions exhibited no correlation to demographic (age, sex) or clinical parameters (tumor entity or localization, resection type, tumor size, number of relapses, and patients status). In contrast, a significant correlation of HERV-F expression with the histological subtype of the STS was observed (*p* = 0.047).

![K vs. F blot **(A)** and violin blot **(B)** exhibiting the distribution of HERV-K and HERV-F mRNA expression in 120 analyzed soft tissue sarcoma (STS) specimens. Violin plot was generated with BoxPlotR (http://shiny. chemgrid.org/boxplotr/).](fmicb-09-00211-g001){#F1}

Association of HERV Expression with Clinicopathological Parameters
------------------------------------------------------------------

In bivariate regression analyses, the association between HERV-K or HERV-F expression and several clinicopathological parameters were tested (see **Table [3](#T3){ref-type="table"}**). Interestingly, HERV-F and HERV-K expression was significantly associated (*r*~S~ = 0.499; *p* = 6.4 × 10^-9^). Both HERV-F and HERV-K expression exhibited a significant inverse association with the actual tumor diameter at surgery (*r*~S~ = -0.309; *p* = 0.001 and *r*~S~ = -0.467; *p* = 7.4 × 10^-8^; respectively). Moreover, HERV-K mRNA expression was significantly inversely associated with BCL2 mRNA expression (*r*~S~ = -0.408; *p* = 0.0002) and miR-199a (*r*~S~ = 0.361; *p* = 0.0004) expression, while solely HERV-F expression was significantly associated with miR-203 expression (*r*~S~ = 0.333; *p* = 0.005). Intriguingly, both HERV-K and HERV-F expression were significantly associated with levels of hypoxia-related genes like HIF-1α mRNA expression (*r*~S~ = 0.444; *p* = 3.0 × 10^-6^ and 0.359; *p* = 0.0002; respectively) or miR-210 expression (*r*~S~ = 0.399; *p* = 0.001 and *r*~S~ = 0.366; *p* = 0.002; respectively). Additionally, both HERV-K and HERV-F expression were significantly associated to H2A.Bbd mRNA expression (*r*~S~ = 0.456; *p* = 0.0009 and *r*~S~ = 0.302; *p* = 0.012, respectively).

###### 

Bivariate correlations (Spearman's rank test; r~s~) of HERV-K or HERV-F mRNA expression with several clinicopathological and molecular parameters.

                                         *r*~s~   *p*                *n*
  ------------- ------------------------ -------- ------------------ -----
  HERV-K mRNA   Tumor diameter           -0.309   **0.001**          120
                BCL2 mRNA expression     -0.408   **0.0002**         77
                miR-210 expression       0.399    **0.001**          71
                miR-203 expression       0.199    0.098              70
                HIF-1a mRNA expression   0.444    **3.0 × 10^-6^**   102
                miR-199a expression      0.361    **0.0004**         94
                H2A.Bbd expression       0.456    **0.0009**         68
                HERV-F mRNA expression   0.499    **6.4 × 10^-9^**   120
  HERV-F mRNA   Tumor diameter           -0.467   **7.4 × 10^-8^**   120
                BCL2 mRNA expression     -0.207   0.071              77
                miR-210 expression       0.366    **0.002**          71
                miR-203 expression       0.333    **0.005**          70
                HIF-1a mRNA expression   0.359    **0.0002**         102
                miR-199a expression      0.116    0.264              94
                H2A.Bbd expression       0.302    **0.012**          68
                HERV-K mRNA expression   0.499    **6.4 × 10^-9^**   120
                                                                     

Significant p-values are marked in bold.

HERV-K or -F Expression and Patients' Survival
----------------------------------------------

In Kaplan--Meier analyses, while HERV-F mRNA expression showed no significant correlation to patients' disease-specific survival, a lower HERV-K mRNA expression was in trend associated with a worsened survival (*p* = 0.08; log rank test). Further, in a multivariate Cox's regression analysis adjusted to the confounders resection type, tumor localization, tumor histotype and staging, there was no significant correlation between HERV-K or HERV-F mRNA expression and patient survival (see Supplementary Figure [S6](#SM1){ref-type="supplementary-material"}). Interestingly, when analyzing the relapse-free survival in Kaplan--Meier analyses, patients with a lower HERV-K mRNA expression exhibited a significantly longer relapse-free survival (*p* = 0.014; log-rank test, see **Figure [2A](#F2){ref-type="fig"}**). A comparable effect was observed in patients with lower HERV-F mRNA expression; however, there it was not significant (*p* = 0.22, see **Figure [2B](#F2){ref-type="fig"}**). Additionally, when analyzing the effect of the HERV-K mRNA expression on the relapse-free survival in a multivariate Cox's regression analysis, an elevated HERV-K mRNA expression was in trend associated with a 1.78-fold increased risk for a relapse (*p* = 0.08). Furthermore, when comparing only patients exhibiting low HERV-F and HERV-K (*n* = 43) with patients exhibiting both elevated HERV-F and HERV-K expression (*n* = 43) in a multivariate Cox's regression analysis, an elevated expression of HERVs was in trend significantly associated with a 2.08-fold increased relative risk for a relapse (*p* = 0.066).

![Survival analyses of STS patients with low or elevated intratumoral HERV-K **(A)** or HERV-F **(B)** expression. Kaplan--Meier survival blots for the relapse-free survival.](fmicb-09-00211-g002){#F2}

Discussion
==========

In this study, we demonstrated that a robust mRNA expression of HERV-K and HERV-F in a cohort of 120 STS samples is detectable, and that the expression of HERV-K and HERV-F is correlated with clinicopathological features and hypoxia-related gene expression. Furthermore, an elevated HERV-K mRNA expression was significantly associated with a shorter relapse-free survival.

There are only few data on the expression of HERVs in STS. Schiavetti and colleagues studied the expression of HERV-K-MEL in sarcoma in comparison to the expression in a patient's sample of melanoma cells. This transcript was detectable in 9/23 (39.1%) of sarcoma samples ([@B40]). There is no data on the expression of HERV-F in sarcoma, however, one report shows a wide expression of HERV-F in tumor cell lines originating from mamma carcinoma, ovarian carcinoma, pancreatic adenocarcinoma, prostate carcinoma, glioblastoma, and others ([@B51]). Interestingly, HERV-F expression was not detected in any somatic tissue tested, with the exception of placenta ([@B51]). These reports are consistent with the assumption, that HERV sequences are normally methylated and therefore transcriptionally inactive, but are hypomethylated and activated during carcinogenesis ([@B30]; [@B22]). Concordantly, the treatment with 5′-azacytdidine, a known DNA methyltransferase inhibitor, activates HERV sequences in diverse tumor cell lines ([@B46]; [@B33]; [@B9]). Therefore, we propose that re-induction of HERVs may also occur during the multi-step process of sarcomagenesis.

Intriguingly, we identified a significant association of the HERV-K and -F expression with those of the hypoxia-related genes HIF-1α and miR-210. HIF-1α is a key regulator of the hypoxic response, and miR-210 is the most prominent microRNA upregulated by hypoxia ([@B31]). There is little knowledge about interactions between HERV expression and hypoxic response. It has been described, that the hypoxia-mimetic CoCl~2~ increases the expression of ERV3 in Hodgkin's lymphoma cell lines, and that this increase in ERV3 expression might be associated with a pro-apoptotic reaction ([@B26]). Other groups demonstrated upregulation of the HERV-W expression in neuroblastoma cell lines due to hypoxic conditions ([@B19]) or upregulation of the HERV-E expression in renal cell carcinomas due to inactivation of the von Hippel-Lindau factor and subsequent stabilization of the oxygen sensor protein HIF-1α ([@B8]). In our *ex vivo* samples, we detected an inverse association between HERV-K and BCL2 mRNA expression, implying that HERV-K overexpression could be associated with apoptosis-induction. However, other reports performed on *in vitro* cell cultures demonstrate that the HERV-K family exerts an anti-apoptotic role ([@B4]). Further research on this contradiction is warranted.

Furthermore, HERV-K and HERV-F expression were both significantly correlated to the mRNA expression of H2A.Bbd, a histone A2 variant encoded on the X chromosome, which is found to be associated with the nucleosomes of transcriptionally active genomic regions ([@B7]). H2A.Bbd was further shown to induce a more relaxed structure of the DNA by destabilizing the nucleosome ([@B2]; [@B10]), which resembles the genomic reorganization induced by histone acetylation in a modification-independent manner ([@B12]). A recent report showed H2A.Bbd to localize temporarily on replication-active DNA regions. By this mechanism, H2A.Bbd is holding the DNA in a more decondensed state, thereby increasing S-phase progression ([@B39]). Thus, it can be speculated that an H2A.Bbd overexpression in patient samples may be associated with a more transcriptionally active genome resulting in an increased chance of reactivation and expression HERV species.

In our patient cohort, we detected a significant association between a lower HERV-K expression and a longer relapse-free survival. This is concordant with previous reports describing a better overall prognosis for patients with a lower HERV-K expression in breast cancer ([@B16]; [@B52]) or hepatocellular carcinoma ([@B35]). Additionally, hypomethylation and subsequent HERV induction was also demonstrated in ovarian carcinoma, and specifically the extent HERV-K hypomethylation was associated with a poor prognosis and therapy resistance in ovarian carcinoma patients ([@B36]; [@B23]).

Conclusion
==========

To the best of our knowledge we present the first report suggesting an involvement of the HERV-K expression in the clinical course of STS. From our *ex vivo* data, we also suggest that HERV-K and -F expression may be regulated directly or indirectly by tumor hypoxia. Furthermore, HERV-K was associated to apoptosis in our samples, therefore may be an interesting therapeutic target.
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